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Sir,
The study reported by Anderson et al (2000) in the August issue of
the BJC demonstrated a sustained improvement in symptom score
with corresponding improvement in QOL, when gemcitabine
(GC) was combined with best supportive care (BSC) vs BSC alone
in advanced NSCLC. Although GC produced an objective
response rate of 19%, with fewer patients requiring radiotherapy
(RT); and the time to RT salvage was longer with GC, there was no
difference in survival. While this study demonstrates once again
that patients’ symptoms and QOL do benefit from palliative
chemotherapy in advanced NSCLC, it does not eliminate one
important factor: the placebo effect associated with receiving
intravenous chemotherapy. 
It is common experience that patients’ expectations from
chemotherapy are greater than those of oncology professionals,
and therefore patients are more willing to undergo chemotherapy
even for small gain (Slevin et al, 1990). The very act of receiving
anticancer therapy gives patients a sense of optimism associated
with the perception that ‘something active is being done’ and that
they are not just ‘wasting away, waiting for the inevitable’. These
factors can be very powerful psychological stimuli which lead
patients to under-report symptoms either because they truly feel
better (placebo effect) or because of underlying fear that reporting
toxicity or symptomatic deterioration may lead to early cessation
of the treatment. 
Where the margin of benefit is so narrow, as in the case of this
study of single agent GC in NSCLC, we feel that blinded
placebo control trials are required to address the true benefit of
cytotoxic chemotherapy in terms of symptomatic improvement
and QOL. 
De Deyn and D’Hooge (1996), in debating the ethical issues
around placebo-controlled trials stated that for such studies to be
considered ethical, it was important that no adequate therapy for
the disease should exist and/or the presumed active treatment
should have side effects. One realizes that the scenario reported by
Anderson et al in their study fits De Deyn’s criterion rather well. 
While we may debate what constitutes an acceptable placebo in
such a study, an appropriate ‘placebo’ may be the same agent
given at a sub-therapeutic dose. The placebo arm would then
require the same degree of monitoring as the treatment arm in
order to confirm that no biological effect is observed on marrow,
renal and hepatic function. Only then can we truly evaluate the
effect of therapeutic doses of any chemotherapeutic agent on
symptoms and QOL, free from observer and patient bias as long as
the study remains blinded. And if such a study were to demon-
strate equivalence in terms of symptom and QOL benefit, it would
have a significant impact on our interpretation of similar studies
where chemotherapy with BSC have been compared to BSC alone.
Maybe we should use the window of opportunity provided by
advanced NSCLC to set up such a study before the opportunity is
lost for good. 
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Sir,
There are now 5 recent randomized trials assessing the value of
chemotherapy versus best supportive care in chemotherapy naive
patients with locally advanced or metastatic non-small cell lung
cancer. The chemotherapy regimens were single agent gemc-
itabine, paclitaxel, vinorelbine in a selected elderly population, the
combination mitomycin C, ifosfamide and cisplatin (MIC) and
single agent docetaxel (Cullen et al, 1999; the Elderly Lung
Cancer Vinorelbine Italian Study Group, 1999; Anderson et al,
2000; Ranson et al, 2000; Roszkowski et al, 2000). There was
evidence of median or 1 year survival advantage in all studies
except the gemcitabine study. However, we note that in the gemcit-
abine study more patients were WHO performance status 2 (72%)
than in the other studies (18–32%), probably because asympto-
matic patients were not eligible for entry into our study. 
All of the studies have assessed quality of life – a difficult area
of research, but all studies have shown some quality of life bene-
fits with chemotherapy. In addition, our study was designed with
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